Aplenzin (Bupropion Hydrobromide)

Description

Aplenzin (bupropion hydrobromide) extended-release tablets, available with a valid prescription, are used for treating major depressive disorder (MDD) and seasonal affective disorder (SAD).

Aplenzin comes in extended-release oral tablets of the following strengths:

• 174 mg
• 348 mg
• 522 mg

Directions

Aplenzin is an antidepressant and should be taken as your doctor has directed. Your doctor will determine your treatment plan. An appropriate Aplenzin dosage will be decided by your doctor based on your diagnosis and how well your kidneys and liver are functioning.

Aplenzin tablets should be stored at 25°C (77°F).

Carefully read the medication guide that comes with your Aplenzin prescription for additional usage instructions.

If any questions or concerns arise, reach out to your doctor or pharmacist.

Ingredients

Bupropion hydrobromide is the active ingredient in Aplenzin.

Glyceryl behenate, polyvinyl alcohol, ethylcellulose, polyethylene glycol, dibutyl sebacate, and povidone are the inactive ingredients. Carnauba wax is also a component of the 174 mg and 348 mg tablets.

Contraindications

Patients who have any of the following conditions should not take Aplenzin:

• Seizure disorder
• Current or any history of bulimia or anorexia nervosa diagnosis
• Known allergy to any of Aplenzin’s ingredients

Patients undergoing sudden discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs should not take Aplenzin.

Aplenzin should not be taken with monoamine oxidase inhibitors (MAOIs) aimed to treat psychiatric disorders or within 14 days of discontinuing an MAOI aimed to treat psychiatric disorders.

Patients receiving linezolid or intravenous methylene blue should not start Aplenzin.

Cautions

• Aplenzin is associated with the following FDA Boxed Warning:
• Children, adolescents, and young adults receiving antidepressants are at increased risk of suicidal thinking and behavior. The development and worsening of suicidal thoughts and behaviors in patients should be monitored.
• Before you start taking Aplenzin, discuss the following with your doctor:
• All the prescription and nonprescription medications you take
• Any allergies you have
• Your current health issues
• Your past medical history
• Your pregnancy or breastfeeding status
• While taking Aplenzin, note the following warnings and precautions:
• Neuropsychiatric adverse events that have occurred while quitting smoking include mood changes, paranoia, delusions, psychosis, hallucinations, homicidal ideation, aggression, hostility, agitation, anxiety, panic, suicidal ideation, suicide attempt, and suicide. Patients who are taking Aplenzin in the process of quitting smoking should be monitored for these adverse events. Contact a healthcare provider right away if you experience any of these events.
• Seizure risk that is dose-related
• High blood pressure
• Patients should be screened for bipolar disorder and monitored for symptoms of mania/hypomania.
• Patients should be advised to contact a healthcare provider right away if they experience psychosis or any other neuropsychiatric reaction.
• Angle-closure glaucoma

Side Effects

Aplenzin side effects include but are not limited to dry mouth, trouble sleeping, nausea, dizziness, sore throat, anxiety, tremor, palpitation, abdominal pain, agitation, sweating, urinary frequency, ringing of the ears, muscle pain, anorexia, and rash.

Immediately inform your doctor of any bothersome or persistent side effects.

Here, you can buy Aplenzin with a valid prescription from your doctor.

Reference

1. Aplenzin. Bridgewater, NJ: Bausch Health US, LLC; 2024.

About Dr. Savannah Muncy (Page Author)

Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....